Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2025)

Karyopharm Therapeutics' Gross Margin history spans 6 years, with the latest figure at 95.31% for Q4 2025.

  • For Q4 2025, Gross Margin fell 107.0% year-over-year to 95.31%; the TTM value through Dec 2025 reached 95.93%, down 21.0%, while the annual FY2025 figure was 95.93%, 9.0% down from the prior year.
  • Gross Margin reached 95.31% in Q4 2025 per KPTI's latest filing, roughly flat from 95.27% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 99.41% in Q4 2021 to a low of 94.39% in Q1 2024.
  • Average Gross Margin over 5 years is 96.56%, with a median of 96.72% recorded in 2024.
  • The largest YoY upside for Gross Margin was 267bps in 2022 against a maximum downside of -498bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 99.41% in 2021, then dropped by -5bps to 94.44% in 2022, then rose by 2bps to 96.69% in 2023, then decreased by 0bps to 96.39% in 2024, then dropped by -1bps to 95.31% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Gross Margin are 95.31% (Q4 2025), 95.27% (Q3 2025), and 97.32% (Q2 2025).